Literature DB >> 10688621

Disposition of methamphetamine and its metabolite amphetamine in brain and other tissues in rats after intravenous administration.

G J Rivière1, W B Gentry, S M Owens.   

Abstract

These studies characterized the concentration-time profile of (+)-methamphetamine [(+)-METH] and its metabolite (+)-amphetamine [(+)-AMP] in the brain and five other tissues after (+)-METH administration. Male Sprague-Dawley rats received a pharmacologically active (+)-METH i.v. bolus dose (1.0 mg/kg) or a nonpharmacologically active s.c. infusion (20 h at 1.2 mg/kg/day). Tissues (n = 3 per time point) were collected for more than four elimination half-lives in the i.v. group, or at a single steady-state time point (20 h) in the s.c. group. Based on data from the area under the concentration-time curves after i.v. dosing, the rank order of (+)-METH tissue accumulation was kidney > spleen > brain > liver > heart > serum with terminal elimination half-life values ranging from 53 to 66 min. (+)-METH concentrations were highest at the first measured time point (2 min) in all tissues except the spleen, which peaked at 10 min. The brain-to-serum concentration ratio rose from 7:1 at 2 min to a peak of 13:1 at 20 min before equilibrating to a constant value of 8:1 at 2 h. Following s.c. (+)-METH dosing, the (+)-METH brain-to-serum concentration ratio was the same as the equilibrated ratio following i.v. dosing. (+)-AMP concentrations peaked at 20 min in all tissues before decaying with terminal elimination half-life values ranging from 68 to 75 min. Analysis of the area under the concentration-time curve molar amounts of (+)-AMP and (+)-METH showed that (+)-AMP accounted for approximately one-third of the drug tissue exposure over time. Thus, these data indicate the importance of both (+)-METH and (+)-AMP in pharmacological effects following i.v. (+)-METH administration.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10688621

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  60 in total

1.  Methamphetamine Impairs IgG1-Mediated Phagocytosis and Killing of Cryptococcus neoformans by J774.16 Macrophage- and NR-9640 Microglia-Like Cells.

Authors:  Lilit Aslanyan; Hiu H Lee; Vaibhav V Ekhar; Raddy L Ramos; Luis R Martinez
Journal:  Infect Immun       Date:  2019-01-24       Impact factor: 3.441

2.  Prolonged exposure of rats to intravenous methamphetamine: behavioral and neurochemical characterization.

Authors:  David S Segal; Ronald Kuczenski; Meghan L O'Neil; William P Melega; Arthur K Cho
Journal:  Psychopharmacology (Berl)       Date:  2005-03-15       Impact factor: 4.530

3.  Sex differences in (+)-amphetamine- and (+)-methamphetamine-induced behavioral response in male and female Sprague-Dawley rats.

Authors:  Alessandra Milesi-Hallé; Donald E McMillan; Elizabeth M Laurenzana; Kelly A Byrnes-Blake; S Michael Owens
Journal:  Pharmacol Biochem Behav       Date:  2007-01-09       Impact factor: 3.533

4.  Chronic treatment of (+)-methamphetamine-induced locomotor effects in rats using one or a combination of two high affinity anti-methamphetamine monoclonal antibodies.

Authors:  Michael D Hambuchen; Daniela Rüedi-Bettschen; Melinda G Gunnell; Howard Hendrickson; S Michael Owens
Journal:  Hum Vaccin Immunother       Date:  2016-05-10       Impact factor: 3.452

5.  Cocaine and methamphetamine induce opposing changes in BOLD signal response in rats.

Authors:  Saeid Taheri; Zhu Xun; Ronald E See; Jane E Joseph; Carmela M Reichel
Journal:  Brain Res       Date:  2016-04-18       Impact factor: 3.252

6.  Methamphetamine inhibits HIV-1 replication in CD4+ T cells by modulating anti-HIV-1 miRNA expression.

Authors:  Chinmay K Mantri; Jyoti V Mantri; Jui Pandhare; Chandravanu Dash
Journal:  Am J Pathol       Date:  2013-10-26       Impact factor: 4.307

7.  Pharmacological effects of two anti-methamphetamine monoclonal antibodies. Supporting data for lead candidate selection for clinical development.

Authors:  Elizabeth M Laurenzana; Misty W Stevens; John C Frank; Michael D Hambuchen; Howard P Hendrickson; Sarah J White; D Keith Williams; S Michael Owens; W Brooks Gentry
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

8.  A new progressive ratio schedule for support of morphine self-administration in opiate dependent rats.

Authors:  Kenneth Grasing; Ning Li; Shaunteng He; Christopher Parrish; John Delich; John Glowa
Journal:  Psychopharmacology (Berl)       Date:  2003-05-06       Impact factor: 4.530

9.  Bioavailability of (+)-methamphetamine in the pigeon following an intramuscular dose.

Authors:  Howard P Hendrickson; William C Hardwick; D E McMillan; S Michael Owens
Journal:  Pharmacol Biochem Behav       Date:  2008-03-29       Impact factor: 3.533

10.  Methamphetamine reduces LTP and increases baseline synaptic transmission in the CA1 region of mouse hippocampus.

Authors:  Jarod Swant; Sanika Chirwa; Gregg Stanwood; Habibeh Khoshbouei
Journal:  PLoS One       Date:  2010-06-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.